Avzivi
Product Images NDC 82143-001

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Avzivi (NDC 82143-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bio-thera Solutions, Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg Carton (100 mg Carton)

Packaging label for Avzivi (bevacizumab-tnjn) injection, 100 mg/4 mL (25 mg/mL) single-dose vial. The label indicates the product is for intravenous infusion after dilution, with instructions to discard unused portion. It is supplied as 1 vial per carton. The labeler is Bio-Thera Solutions, Ltd. Storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F). The label also lists inactive ingredients and notes the product contains no preservative.*

FDA Label Image

400 mg Carton (400 mg Carton)

Carton label for Avzivi (bevacizumab-twnj) Injection by Bio-Thera Solutions, Ltd. It contains one 16 mL single-dose vial with 400 mg per 16 mL (25 mg/mL) for intravenous infusion after dilution. The label includes storage instructions, contents, and a placeholder for the barcode.*

FDA Label Image

Fig-01 (Fig 01)

A survival curve chart showing the proportion surviving over a duration of up to 30 months. It compares two groups: IFL plus placebo (gray line) and IFL plus bevacizumab (black line), with the latter showing higher survival over time. The number of patients at risk at various time points is listed below the x-axis.*

FDA Label Image

Fig-02 (Fig 02)

A survival curve chart illustrating the proportion surviving over 48 study months, comparing two randomized treatments: chemotherapy alone and chemotherapy combined with bevacizumab. The x-axis represents study months, and the y-axis shows the proportion surviving. Below the graph, numbers of patients at risk are listed for each treatment group at various time points.*

FDA Label Image

Fig-03 (Fig 03)

A survival curve chart comparing the proportion of patients surviving over a duration of up to 50 months. The graph shows two lines representing two groups: one labeled PC with 444 patients and another labeled PC plus bevacizumab with 434 patients. The x-axis measures the duration of survival in months, while the y-axis shows the proportion surviving. A table below the graph lists the number of patients at risk at various time points for both groups.*

FDA Label Image

Fig-04 (Fig 04)

A Kaplan-Meier plot showing progression-free survival over 24 months for two groups: Placebo + IFN-alfa (n=322) and Bevacizumab + IFN-alfa (n=327). The y-axis represents the proportion progression free, and the x-axis represents time in months. The graph includes numbers of patients at risk at specified time points.*

FDA Label Image

Fig-05 (Fig 05)

A Kaplan-Meier survival curve comparing overall survival in months between two groups: one receiving chemotherapy alone and another receiving chemotherapy plus bevacizumab. The y-axis shows the proportion of overall survival, and the x-axis shows time in months. The graph includes a risk table with patient numbers at various time points for each group.*

FDA Label Image

Fig-06 (Fig 06)

A Kaplan-Meier survival curve showing progression-free survival over time (months) comparing two groups: CT (red line, n=182) and CT+BV (blue line, n=179). The y-axis represents the proportion of progression-free patients, and the x-axis shows duration in months. Numbers at risk for each group are listed below the graph at multiple time points up to 24 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.